Daniel Morgensztern MD

Associate Professor, Washington University School of Medicine, St. Louis, MO.

4921 Parkview Pl# DvSt. Louis, MO 63110
Phone+1 800-647-2098
Fax+1 314-362-3192

Dr. Morgensztern is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Morgensztern's full profile Already have an account?

Education & Training

University of Miami/Jackson Health SystemResidency, Internal Medicine, 1998 - 2001
Tech- Ed Fndn Souza Marques Sch MedClass of 1995

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MO State Medical License 2013 - 2027
CT State Medical License 2010 - 2013
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction
TERMINATED
PHASE2
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
COMPLETED
PHASE2
Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 16
TERMINATED
PHASE2

Publications & Presentations

PubMed

Post-Operative Radiation Therapy for Non-Small Cell Lung Cancer Patients With Higher Positive to Examined Lymph Node Ratio is Associated With Improved Overall Survival.
Temitope Agabalogun, Brendan T. Heiden, M.B. Spraker, S.N. Badiyan, G.R. Vlacich
International Journal of Radiation Oncology Biology Physics. 2021-11-01
KEYLYNK-012: A Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy (CCRT) Followed by Pembrolizumab With or Without Olaparib vs. CCRT Followed by Dur...
Salma K. Jabbour, Byoung Chul Cho, Emilio Bria, Terufumi Kato, Jaishree Bhosle
International Journal of Radiation Oncology Biology Physics. 2021-11-01
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
David E Gerber, D Ross Camidge, Daniel Morgensztern, Jeremey Cetnar, Ronan J Kelly
Lung cancer (Amsterdam, Netherlands). 2019-11-19

Journal Articles

Recurrent WNT Pathway Alterations Are Frequent in Relapsed Small Cell Lung Cancer
Saiama N. Waqar, Daniel Morgensztern, Robert S. Fulton, Ramaswamy Govindan, Nature

Lectures

Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC) after checkpoint inhibitor treatment failure.
2019 ASCO Annual Meeting - 6/1/2019
Multicenter phase II trial of RRx-001 in previously treated SCLC.
2019 ASCO Annual Meeting - 6/1/2019
Yale Cancer Center Evening Oncology Series: Lung Cancer
Yale CME, New Haven, Connecticut - 5/10/2012

Authored Content

Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non-Small-Cell Lung CancerFebruary 2018

Press Mentions

Safety and Efficacy of Zimberelimab (AB122) in Combination with Domvanalimab (AB154) and Etrumadenant (AB928) in Patients with Previously Treated Non-Small Cell Lung CancerMarch 10th, 2021
Adding a Vaccine to Immunotherapy in Lung Cancer: Will It Improve Outcomes?March 4th, 2019
Heat Biologics, Inc. (NASDAQ:HTBX) Files an 8-K Regulation FD DisclosureFebruary 28th, 2019